This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Davies, T. A.
Right arrow Articles by Dagan, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Davies, T. A.
Right arrow Articles by Dagan, R.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2008, p. 378-381, Vol. 52, No. 1
0066-4804/08/$08.00+0     doi:10.1128/AAC.01068-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Characterization and Dynamics of Middle Ear Fluid and Nasopharyngeal Isolates of Streptococcus pneumoniae from 12 Children Treated with Levofloxacin{triangledown}

Todd A. Davies,1* Eugene Leibovitz,2 Gary J. Noel,1 David F. McNeeley,1,{dagger} Karen Bush,1 and Ron Dagan2

Johnson & Johnson Pharmaceutical Research and Development, LLC, Raritan, New Jersey,1 Pediatric Infectious Disease Unit, Soroka University Medical Center and Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel2

Received 13 August 2007/ Returned for modification 12 September 2007/ Accepted 29 October 2007

Children who had acute otitis media and were treated with levofloxacin were assessed for the emergence of fluoroquinolone-resistant Streptococcus pneumoniae. Nasopharynx cultures were obtained from patients at the entry to and during levofloxacin therapy. All nasopharynx isolates (n = 59) from 12 children were levofloxacin susceptible without parC/E or gyrA/B mutations. Pneumococcal nasopharynx persistence was not associated with levofloxacin resistance.

* Corresponding author. Mailing address: Johnson & Johnson Pharmaceutical Research and Development, LLC, Room B225, 1000 Route 202, Raritan, NJ 08869. Phone: (908) 707-3465. Fax: (908) 707-3501. E-mail: tdavies{at}prdus.jnj.com

{triangledown} Published ahead of print on 12 November 2007.

{dagger} Present address: Tibotec, Inc., Yardley, PA.

Antimicrobial Agents and Chemotherapy, January 2008, p. 378-381, Vol. 52, No. 1
0066-4804/08/$08.00+0     doi:10.1128/AAC.01068-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»